



Access to Kidney Cancer Medicines in the UK – January 2023

Trade name <i>Manufacturer</i>	Generic name	How it works	Indication	Availability
First-line treatments				
Keytruda <i>MSD</i>	Pembrolizumab	Immunotherapy: anti-PD1 checkpoint inhibitor infusion	Adjuvant treatment for locally advanced moderate to high risk RCC	Available on the NHS
Kisplyx plus Keytruda <i>Eisai/MSD</i>	Lenvatinib in combination with pembrolizumab	Targeted therapy plus immunotherapy: VEGF tyrosine kinase inhibitor (TKI) plus anti-PD1 checkpoint inhibitor Infusion plus oral medication	First-line treatment for advanced RCC	Available on the NHS in England and Wales. Restricted access under a Patient Access Scheme (PAS) in Scotland.
Cabometyx plus Opdivo <i>Ipsen/BMS</i>	Cabozantinib in combination with nivolumab	Targeted therapy plus immunotherapy: VEGF tyrosine kinase inhibitor (TKI) plus anti-PD1 checkpoint inhibitor Oral medication plus infusion	First-line treatment for advanced RCC	Restricted access under a Patient Access Scheme (PAS) in Scotland. Not available on the NHS in England and Wales
Bavencio plus Inlyta <i>Merck/Pfizer</i>	Avelumab in combination with axitinib	Immunotherapy plus targeted therapy: Anti-PD-L1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion plus oral medication	First-line treatment for advanced/metastatic RCC	Available via the Cancer Drugs Fund (CDF) for patients in England and Wales. Available on the NHS in Scotland
Keytruda plus Inlyta <i>MSD/Pfizer</i>	Pembrolizumab in combination with axitinib	Immunotherapy plus targeted therapy: Anti-PD1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion plus oral medication	First-line treatment for advanced RCC	Available on the NHS in Scotland under a Patient Access Scheme (PAS). Not available on the NHS in England and Wales
Opdivo plus Yervoy <i>BMS</i>	Nivolumab in combination with ipilimumab	Immunotherapy: Anti-PD1 checkpoint inhibitor plus anti-	First-line treatment for intermediate and poor risk advanced RCC	Available on the NHS

		CTLA4 inhibitor Infusion		
Sutent <i>Pfizer</i>	Sunitinib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for metastatic RCC	Available on the NHS
Votrient <i>Novartis</i>	Pazopanib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for metastatic RCC	Available on the NHS
Cabometyx <i>Ipsen</i>	Cabozantinib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for locally advanced/metastatic RCC	Available on the NHS
Fotivda <i>Aveo/Eusa</i>	Tivozanib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for metastatic RCC	Available on the NHS
Second-line treatments				
Kisplyx plus Afinitor <i>Eisai, Novartis</i>	Lenvatinib in combination with everolimus	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) plus mTOR inhibitor Oral medication	Second-line treatment for advanced RCC	Available on the NHS
Inlyta <i>Pfizer</i>	Axitinib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	Second-line treatment for advanced RCC	Available on the NHS
Second line and beyond treatments				
Opdivo <i>BMS</i>	Nivolumab	Immunotherapy: Anti-PD1 checkpoint inhibitor	Second/third-line treatment for advanced/metastatic RCC	Available on the NHS
Cabometyx <i>Ipsen</i>	Cabozantinib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	Second/third-line treatment for advanced RCC after VEGF-TKI treatment	Available on the NHS
Afinitor <i>Novartis</i>	Everolimus	Targeted therapy: mTOR inhibitor Oral medication	Second/third-line treatment for advanced RCC	Available on the NHS in England, Scotland and Wales

Other treatments for advanced kidney cancer				
Proleukin <i>Clinigen</i>	Interleukin 2 (IL 2)	Immunotherapy: Cytokine Infusion	Advanced/metastatic RCC	Available to pre-selected patients only at specialist research sites (Christie Hospital, Manchester). Not funded by the NHS
Torisel <i>Pfizer</i>	Temsirolimus	Targeted therapy: mTOR inhibitor Oral medication	First-line treatment for advanced RCC of poor prognosis	Not routinely available on the NHS Access via individual funding request*
Avastin <i>Roche</i>	Bevacizumab	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Infusion	First-line treatment for advanced/metastatic RCC in combination with interferon alpha	Not routinely available on the NHS Access via individual funding request*
Nexavar <i>Bayer</i>	Sorafenib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First/second-line treatment for advanced/metastatic RCC	Not routinely available on the NHS Access via individual funding request*
Tecentriq plus Avastin <i>Roche</i>	Atezolizumab in combination with bevacizumab	Immunotherapy plus targeted therapy: Anti-PD-L1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion	First-line treatment for locally advanced/metastatic RCC	Appraisal suspended
Xgeva <i>Amgen</i>	Denosumab	Immunotherapy: RANK ligand inhibitor Injection	Cancer that has spread to the bones as an alternative to bisphosphonates	Available on the NHS

Clinical Trials for Kidney Cancer - Please go to our [clinical trials database](#) for a complete list of all clinical trials for kidney cancer in the UK:

*Individual funding requests may be submitted via the following route:

- England and Northern Ireland: [Individual Funding Request \(IFR\)](#)
- Wales: [Individual Patient Funding Request \(IPFR\)](#)
- Scotland: [Individual Patient Treatment Request \(IPTR\)](#)